Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex

References

• Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Antibodies to combat viral infections: development strategies and progress. Nat Rev Drug Discov. 2022;21:676–11. doi:10.1038/s41573-022-00495-3. PMID: 35725925.
   PubMed Web of Science ®Google Scholar
• Ferrara F, D’Angelo S, Erasmus MF, Teixeira AA, Leal-Lopes C, Spector LP, Pohl T, Fanni A, Cocklin S, Bradbury ARM. Pandemic’s silver lining. MAbs. 2022;14:2133666. doi:10.1080/19420862.2022.2133666. PMID: 36253351.
   PubMed Web of Science ®Google Scholar
• Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184(12):3086–108. PMID: 34087172. doi:10.1016/j.cell.2021.05.005.
   PubMed Web of Science ®Google Scholar
• Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. 2022. Monoclonal antibody therapies against SARS-CoV-2. The lancet infectious diseases. PMID: 35803289 22(11):e311–e26. doi:10.1016/S1473-3099(22)00311-5
   Google Scholar
• Ismail AM, Elfiky AA. 2020. SARS-CoV-2 spike behavior in situ: a Cryo-EM images for a better understanding of the COVID-19 pandemic. Signal transduction and targeted therapy. PMID: 33127886 5(1):252. doi:10.1038/s41392-020-00365-7
   Google Scholar
• Ke Z, Oton J, Qu K, Cortese M, Zila V, McKeane L, Nakane T, Zivanov J, Neufeldt CJ, Cerikan B, et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature. 2020;588(7838):498–502. doi:10.1038/s41586-020-2665-2. PMID: 32805734.
   PubMed Web of Science ®Google Scholar
• Deshpande A, Harris BD, Martinez-Sobrido L, Kobie JJ, Walter MR. Epitope classification and RBD binding properties of neutralizing antibodies against SARS-CoV-2 variants of concern. Front Immunol. 2021;12:691715. doi:10.3389/fimmu.2021.691715. PMID: 34149735.
   PubMed Web of Science ®Google Scholar
• Finkelstein MT, Mermelstein AG, Parker Miller E, Seth PC, Stancofski ED, Fera D. Structural analysis of neutralizing epitopes of the SARS-CoV-2 spike to guide therapy and vaccine design strategies. Viruses. 2021;13(1):134. PMID: 33477902. doi:10.3390/v13010134.
   PubMed Web of Science ®Google Scholar
• Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JH, Ferrin TE. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 2018;27(1):14–25. PMID: 28710774. doi:10.1002/pro.3235.
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 2021;30(1):70–82. PMID: 32881101. doi:10.1002/pro.3943.
   PubMed Web of Science ®Google Scholar
• Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Peacock SJ, Barclay WS, Barclay, de Silva TI TI, Towers GJ, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;1–16. PMID: 36653446. doi:10.1038/s41579-022-00841-7.
   Web of Science ®Google Scholar
• Scovino AM, Dahab EC, Vieira GF, Freire-de-Lima L, Freire-de-Lima CG, Morrot A. SARS-CoV-2‘s variants of concern: a brief characterization. Front Immunol. 2022;13:834098. doi:10.3389/fimmu.2022.834098. PMID: 35958548.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and their emerging variants with escape mutations. Front Immunol. 2022;13:801522. doi:10.3389/fimmu.2022.801522. PMID: 35222380.
   PubMed Web of Science ®Google Scholar
• Cox M, Peacock TP, Harvey WT, Hughes J, Wright DW, Willett BJ, Thomson E, Gupta RK, Peacock SJ, Robertson DL, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol. 2023;21(2):112–24. doi:10.1038/s41579-022-00809-7. PMID: 36307535.
   PubMed Web of Science ®Google Scholar
• Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host & Microbe. 2021;29(3):463–476.e6. PMID: 33592168. doi:10.1016/j.chom.2021.02.003.
   PubMed Web of Science ®Google Scholar
• Yang WT, Huang WH, Liao TL, Hsiao TH, Chuang HN, Liu PY. SARS-CoV-2 E484K mutation narrative review: epidemiology, immune escape, clinical implications, and future considerations. Infect Drug Resist. 2022;15:373–85. doi:10.2147/IDR.S344099. PMID: 35140483.
   PubMed Web of Science ®Google Scholar
• Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–63. doi:10.1038/s41586-021-04385-3. PMID: 35016194.
   PubMed Web of Science ®Google Scholar
• Shah M, Woo HG. Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies. Front Immunol. 2021;12:830527. doi:10.3389/fimmu.2021.830527. PMID: 35140714.
   PubMed Web of Science ®Google Scholar
• Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-Gonzalez A, Glasner DR, Reyes KR, Gliwa AS, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021;184(13):3426–37.e8. doi:10.1016/j.cell.2021.04.025. PMID: 33991487.
   PubMed Web of Science ®Google Scholar
• Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284–94.e9. doi:10.1016/j.cell.2020.07.012. PMID: 32730807.
   PubMed Web of Science ®Google Scholar
• Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010–14. doi:10.1126/science.abd0827. PMID: 32540901.
   PubMed Web of Science ®Google Scholar
• Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, Mok CKP, Wilson IA. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368(6491):630–33. PMID: 32245784. doi:10.1126/science.abb7269.
   PubMed Web of Science ®Google Scholar
• Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115–19. doi:10.1038/s41586-020-2380-z. PMID: 32454513.
   PubMed Web of Science ®Google Scholar
• Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290–95. doi:10.1038/s41586-020-2349-y. PMID: 32422645.
   PubMed Web of Science ®Google Scholar
• Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, Zhu Q, Zhang X, Zheng Y, Geng C, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020;182(1):73–84.e16. doi:10.1016/j.cell.2020.05.025. PMID: 32425270.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, Li Z, Li S, Bi Y, Yang Y, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020;368(6496):1274–78. doi:10.1126/science.abc2241. PMID: 32404477.
   PubMed Web of Science ®Google Scholar
• Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–24. doi:10.1038/s41586-020-2381-y. PMID: 32454512.
   PubMed Web of Science ®Google Scholar
• Rujas E, Kucharska I, Tan YZ, Benlekbir S, Cui H, Zhao T, Wasney GA, Budylowski P, Guvenc F, Newton JC, et al. Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. Nat Commun. 2021;12(1):3661. doi:10.1038/s41467-021-23825-2. PMID: 34135340.
   PubMed Web of Science ®Google Scholar
• Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, Malyutin AG, Sharaf NG, Huey-Tubman KE, Lee YE, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682–87. doi:10.1038/s41586-020-2852-1. PMID: 33045718.
   PubMed Web of Science ®Google Scholar
• Kreye J, Reincke SM, Kornau HC, Sanchez-Sendin E, Corman VM, Liu H, Yuan M, Wu NC, Zhu X, Lee CD, et al. A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model. Cell. 2020;183(4):1058–69.e19. doi:10.1016/j.cell.2020.09.049. PMID: 33058755.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-Fregni C, Pinto D, Rosen LE, Bowen JE, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024–42.e21. doi:10.1016/j.cell.2020.09.037. PMID: 32991844.
   PubMed Web of Science ®Google Scholar
• Tortorici MA, Beltramello M, Lempp FA, Pinto D, Dang HV, Rosen LE, McCallum M, Bowen J, Minola A, Jaconi S, et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science. 2020;370(6519):950–57. doi:10.1126/science.abe3354. PMID: 32972994.
   PubMed Web of Science ®Google Scholar
• Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650–55. doi:10.1126/science.abc6952. PMID: 32571838.
   PubMed Web of Science ®Google Scholar
• Lv Z, Deng YQ, Ye Q, Cao L, Sun CY, Fan C, Huang W, Sun S, Sun Y, Zhu L, et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020;369(6510):1505–09. doi:10.1126/science.abc5881. PMID: 32703908.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Ravetch JV. Fcgamma receptor pathways during active and passive immunization. Immunol Rev. 2015;268:88–103. doi:10.1111/imr.12343. PMID: 26497515.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34–47. PMID: 18064051. doi:10.1038/nri2206.
   PubMed Web of Science ®Google Scholar
• Tada M, Aoyama M, Ishii-Watabe A. Fcγ receptor activation by human monoclonal antibody aggregates. J Pharm Sci. 2020;109(1):576–83. PMID: 31676270. doi:10.1016/j.xphs.2019.10.046.
   PubMed Web of Science ®Google Scholar
• Tada M, Suzuki T, Ishii-Watabe A. Development and characterization of an anti-rituximab monoclonal antibody panel. MAbs. 2018;10(3):370–79. PMID: 29309213. doi:10.1080/19420862.2018.1424610.
   PubMed Web of Science ®Google Scholar
• Tada M, Ishii-Watabe A, Suzuki T, Kawasaki N, Zhou P. Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies. PLos One. 2014;9(4):e95787. PMID: 24752341. doi:10.1371/journal.pone.0095787.
   PubMed Web of Science ®Google Scholar
• Huo J, Zhao Y, Ren J, Zhou D, Duyvesteyn HME, Ginn HM, Carrique L, Malinauskas T, Ruza RR, Shah PNM, et al. Neutralization of SARS-CoV-2 by destruction of the prefusion spike. Cell Host & Microbe. 2020;28:497. doi:10.1016/j.chom.2020.07.002. PMID: 32910920.
   PubMed Web of Science ®Google Scholar
• Ankerhold J, Giese S, Kolb P, Maul-Pavicic A, Voll RE, Goppert N, Ciminski K, Kreutz C, Lother A, Salzer U, et al. Circulating multimeric immune complexes contribute to immunopathology in COVID-19. Nat Commun. 2022;13:5654. doi:10.1038/s41467-022-32867-z. PMID: 36163132.
   PubMed Web of Science ®Google Scholar
• Junqueira C, Crespo A, Ranjbar S, de Lacerda LB, Lewandrowski M, Ingber J, Parry B, Ravid S, Clark S, Schrimpf MR, et al. FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. 2022;606(7914):576–84. doi:10.1038/s41586-022-04702-4. PMID: 35385861.
   PubMed Web of Science ®Google Scholar
• Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463–71. PMID: 9765382. doi:10.1128/JVI.72.11.8463-8471.1998.
   PubMed Web of Science ®Google Scholar